Introduction: Sickle cell disease (SCD) is a genetically inherited, recessive mutation of the haemoglobin βS-gene. Each year, over 300,000 babies are born with SCD, which will have a significant impact on their quality of life and average life expectancy. Currently, for SCD to be tested prenatally, foetal DNA is extracted by amniocentesis, chorionic villus sampling or cordocentesis, and then analysed by polymerase chain reaction (PCR), for instance. These procedures increase the risk of foetal miscarriage by less than 0.5%. SCD may, however, be tested non-invasively using cell-free foetal DNA (cffDNA), which is extracted from maternal blood plasma. In this study, the current accuracy of using cffDNA testing for non-invasive prenatal diagnosis (NIPD) of SCD will be shown.
INTRODUCTION
SCD is defined as a hereditary (autosomal recessive monogenic) haemoglobinopathy, which includes sickle cell anaemia (HbSS disease) and various compound heterozygous genotypes, for example, sickle cell HbSC disease or sickle cell β-thalasaemia disease (HbSβthal) characterised by chronic haemolytic anaemia and vaso-occlusive complications. It is globally amongst the most common genetic disorders, affecting approximately 30 million people [1] [2] [3] . SCD is associated with high lifetime morbidity and premature mortality, as described in the most recent Global Burden of Disease study. Approximately 7% of the world's populations are healthy carriers of haemoglobinopathies, resulting in 300,000 newborns severely affected with SCD annually [4] .
In South East London, close to 0.3% of newborns are affected by SCD, whereas the average in the United Kingdom is 0.05%, with SCD being the most common reason for invasive prenatal diagnostic testing, reporting approximately 350 cases each year [2, 5, 6] .
Due to the severity of this disease and the limited treatment options, prenatal diagnosis by invasive testing is offered in many countries as part of a national prevention programme, with a procedure-related risk of miscarriage being reported as 0.05% for chorionic villus sampling and <0.5% for amniocentesis [5, 7, 8] , which are the current gold standards for prenatal testing, and are approximately 100% accurate [7] .
The discovery of cffDNA in maternal blood circulation has led to the possibility of NIPT or NIPD mitigating the invasive procedure-related risk of miscarriage [5, 7] . This discovery has been applied successfully for RhD genotype, trisomy 21, 13 and 18 detection, as well as foetal sex determination (reporting 96.6% sensitivity and 98.6% specificity using this technique) [9, 10] . CffDNA is detectable very early during pregnancy, with the mean quantity of cffDNA during the first and second trimesters being approximately 10% of the total amount of cell-free DNA [2] . SCD may be tested non-invasively, therefore, patients may favour this technique as, apart from being safe, it is also accurate [2, 11] . This systematic manuscript review was undertaken to ascertain the available data to determine whether using cffDNA for NIPD of SCD has a sensitivity and specificity that can match the gold standard and could, therefore, potentially be used in a clinical setting.
METHODS

Search Strategy
A systematic review and meta-analysis was performed whilst adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guideline and Meta-Analysis of Observational Studies in Epidemiology criteria [12] and SEDATE guidelines [13] . This systematic review was registered apriori (Reference Number: CRD42016037239). The following databases were searched for previous work undertaken between January 1995 and April 2016. The databases researched were PubMed, Cochrane Library, Web of Science, Scopus, Google Scholar, Science Direct and Ovid (Limitations: research, reviews, author manuscripts); the search criteria are presented in Table 1 . Abstracts and full text articles were assessed by two authors (LS and EON) in order to select the articles that met the inclusion criteria. Further detailed investigations of the relevant original and review articles were undertaken to identify applicable studies. There were no language restrictions.
Study Selection
The studies incorporated in the systematic review met the following criteria:
•
The study design was a cohort study;
• The exposure of interest was pregnant women at risk of having a baby with SCD or sickle cell trait;
• The studies contained specific data on the genetic testing of cffDNA from maternal plasma or serum, as part of an on-going study;
• The studies performed a data comparison to the gold standard, or tested for the genotype at birth;
• The selected studies describe results gained from each study compared to a control group, which presents as patients who are not at risk of having a SCD or sickle cell trait baby [14, 15] .
Reviews, editorials, non-human studies, and published letters without data were excluded. No studies including data pertaining to twin studies using cffDNA for NIPD of SCD were included.
Study Characteristics
Study Outcome
The aim of this study was to perform a systematic review and subsequent meta-analysis on NIPD of SCD. All publications retrieved as a result of the search "Sickle cell disease" and "prenatal" and "diagnosis" and "foetal blood"
"Sickle cell disease" or "sickle cell anaemia" and "prenatal" and "diagnosis" and "non-invasive" "Sickle cell disease" and "prenatal" and "diagnosis" and "free foetal DNA" "Sickle cell disease" and "prenatal" and "diagnosis" and "non-invasive" and "free foetal DNA" "Sickle cell disease" and "detection" and "non-invasive" and "prenatal" and "cell-free DNA" "Sickle cell disease" or "sickle cell anaemia" and "antenatal" and "diagnostic" and "minimally invasive" and "free foetal DNA" "Sickle cell disease" and "prenatal" and "haemoglobinopathy" and "diagnosis" and "non-invasive" strategies, previously outlined in the Study Selection, were systematically appraised to compile a list of manuscripts containing research data on the use of cffDNA for NIPD of SCD. A meta-analysis was then performed on the data retrieved from the final selection of manuscripts to determine the proportion of correct diagnosis results. Finally, a conclusion was drawn as to whether the level of accuracy and associated risk to the mother and foetus from tests using cffDNA technique should be recommended for clinical use, with regards to NIPD of SCD [15, 16] .
Intervention
The intervention for each of the studies analysed in this review was the technique for prenatal non-invasive SCD diagnosis, in the form of cffDNA, which was extracted from a maternal blood sample and tested for the sickle cell mutation, for example, by PCR [2, 15, 16] .
Comparator
For each of the selected studies used in the metaanalysis, the result of the diagnosis using cffDNA was compared to the gold standard of testing, being either amniocentesis or chorionic villus sampling. In some cases, genetic testing to confirm foetal genotype was assessed at birth, as a secondary determination [16] .
Study Design
The studies included in the meta-analysis were prospective cohort studies, therefore, the specific data on the genetic testing of cffDNA from maternal plasma or serum were collected as part of an on-going study, allowing for PCRs or single nucleotide polymorphism (SNP) analysis to be performed at the time of blood sampling. This was then followed up by comparison to the gold standard, or by testing of the genotype at birth. The results gained from each study were compared to a control group, which was presented as pregnant patients who were not at risk of having a SCD or sickle cell trait baby [14, 15] .
Study Population
The study population selected for this systematic review were pregnant women, of whom either themselves, the father of the foetus, or both parents were a SCD carrier or SCD patient [14, 16, 17] .
Data Extraction
Due to the limited appropriate data retrieved from the systematic review, those papers which contained usable and relevant data to NIPD for SCD, whilst conforming to the restrictions outlined in Study Selection, were included in the meta-analysis. A total of 3,631 papers were identified and screened following the search stage during the systematic review, to which only five papers could be applied to the NewcastleOttawa Quality Assessment Scale (see Figure 1) , as well as the QUADAS-II quality assessment guideline [18] (see Table 2 ), and, therefore, were included in the meta-analysis. The five studies described the relevant data retrieved from a total of 139 pregnant patients who were at risk of having a baby with SCD.
Quality Assessment
The manuscripts included in the systematic review were subjected to quality assessment scoring using the Newcastle-Ottawa Quality Assessment Scale for cohort studies [19] and the QUADAS-II assessment table, to determine the potential for any bias within the studies which were to be included in the meta-analysis. Those manuscripts to which the Newcastle-Ottawa Quality Assessment Scale could not be applied, due to the absence of relevant data, were excluded from the meta-analysis. Four papers and one abstract of a paper to which the quality assessment scale could be applied were used in the final data extraction stage. These manuscripts were studies by Cheung et al., (1996) [20] , Barrett et al., (2012) [23] . The papers were scored as low, medium or high quality according to the QUADAS-II assessment table, and out of 8* according to the Newcastle-Ottawa Quality Assessment Scale, by their relevance to the answers of questions under three subheadings:
• Selection, whereby the study representatives, selection of participants, ascertainment and demonstration of exposure are determined;
• Comparability, whereby the use and propriety of a control group is assessed;
• Study Outcome, whereby the assessment of outcome, longevity of the study and follow up of the study are assessed.
The study with the highest quality score was that by Phylipsen et al., (2013) [21] , with 8*/8* (Medium QUADAS-II score). The study with the lowest score was the abstract of a paper by Fielding et al., (2013) [22] with 3*/8* (Low QUADAS-II score), as the abstract contained little information which would allow for the generation of a quality assessment score and was, therefore, of low quality for the purposes of this study. Overall, the quality of the studies used in the data synthesis was of a satisfactory standard, therefore, showed little bias. The risk of bias across these papers could be increased by the omission of false positive or false negative data, as well as the data from the controls. If the data from the control group was inaccurate, then the data retrieved from method and subsequent results would be inaccurate.
Statistical Analysis
It was originally intended that the data retrieved as part of the systematic review would be presented in the form of a meta-analysis and a subsequent Forest Plot, in order to determine the sensitivity and specificity of the use for NIPD for the determination of foetal SCD. However, the lack of homogeneity between the independent studies due to the uses of differing methods and techniques between the studies [24] , as well as the inability to distinguish between the true positive and true negative values from the data retrieved, lead to the determination that it was more appropriate to present the data as a Forest Plot metaanalysis (see Figure 2) indicating the proportion of correct diagnosis results for the use of cffDNA for the diagnosis of SCD in each study. The meta-analysis was carried out using Meta-DiSc, version 1.4 [25] . The proportions were compared using the DerSimonian and Laird approach, adapted for proportions [26] .
RESULTS
In order to assess how accurate or relevant the evidence proffered by the data collected from the systematic review was, the validity of the studies was interrogated. The evidence presented in the studies was deemed to be of good strength, as each paper described a moderate success rate. Despite some papers containing a smaller number of participants than others, the combined research indicated that the use of cffDNA for NIPD for SCD has the potential for a high degree of accuracy and consistency [15] , despite not yet indicating an accuracy that would allow this technique to be used in clinical practice.
From the systematic review that was performed, four manuscripts and one abstract of a paper were identified to contain data on NIPD for SCD (see Table  3 ). As shown in Table 3 , the correct diagnosis from use of cffDNA to test prenatally for SCD ranged from 76.67% to 100% (with a weighted average of 81.30%). However, two studies (Cheung et al., (1998) [20] and Phylipsen et al., (2012) [23] yielded a 100% success rate. These two studies were made up of two and thirteen test subjects respectively, therefore, the high percentage accuracy and low cohort size have an impact on the reliability of the average percentage accuracy of the data. That being said, the remaining three studies with the largest cohorts still returned an individual accuracy of over 75%. The incorrect data, for the purpose of this meta-analysis, indicates the incorrect and unclassified data retrieved from the studies. The incorrect diagnosis rate ranged from 0% to 23.33%, with a weighted average of 18.70%. The study with the highest inaccuracy percentage was that by Yenilmez et al., (2013) [23] , with 23.33% inaccuracy. Despite describing the correct determination of sickle cell mutations in 30/30 foetuses using high resolution melting (HRM) analysis (which was then confirmed by chorionic villus sampling), the technique did not distinguish between foetuses with SCD (7/30) and those with sickle cell trait (23/30). *In this table, the data classified by each of the studies as incorrect or unclassified results have been combined under one subheading of "Incorrect Result" or "Incorrect Diagnosis", in order to easily distinguish between those results which produced a correct foetal diagnosis and those which did not.
As can be seen in Figure 2 , the study by Barrett et al., (2012) [2] shows a smaller confidence interval than the study by Cheung et al., (1996) [20] , due to the larger study size by Barrett et al., (2012) [2] . Furthermore, the final result of the pooled sensitivity indicates a result which is closest to the result from the study by Barrett et al., (2012) [2] , thereby indicating that the results gained from this study describe the data which is closest to the true sensitivity of using cffDNA to test for SCD.
DISCUSSION
Summary of Evidence
The analysis of data collected during the systematic review shows that currently NIPD for SCD achieves approximately 81.30% accurate diagnosis and 18.70% inaccurate diagnosis, which is significantly less than the current accuracy of the gold standard for prenatal testing. Therefore, extensive future research to enhance the accuracy of this technique will render invasive testing for this condition obsolete, and mitigate procedure related risk of miscarriage.
Despite the use of cffDNA for NIPD for SCD having first been suggested over 20 years ago (as was seen from the study by Cheung et al., (1996) [20] , there are very few studies detailing specific data on the accuracy and reliability of cffDNA as a diagnostic tool for SCD. As a result, out of over 3,600 papers scanned for this systematic review, only four full manuscripts and one paper abstract were found to contain any usable and relevant data. Therefore, the need for further research into this field is absolute. Further research will be able to design novel techniques for detection and analysis of cffDNA, in order to most accurately diagnose the foetal genotype.
Limitations
During the formation of this systematic review, it was evident that an insufficient number of clinical trials producing data regarding the use of NIPD for SCD have been undertaken, as of the date of submission of this study. Furthermore, there was significant heterogeneity with regards to the methods of cffDNA retrieval and testing [16] between the studies found during the systematic review. For example, Phylipsen et al., (2012) [21] and Yenilmez et al., (2013) [23] used SNPs to detect gene mutations, whereas Cheung et al., (1998) [20] , Barrett et al., (2012) [2] and Fielding et al., (2013) [22] , used PCR. Consequently, until there is a standardised method by which this technique is performed, there may be no detailed statistical analysis performed on the available data [16] , in order to find the true strength of evidence present for the sensitivity and specificity for the use of cffDNA for NIPD of SCD [27] , and thus generate a true odds ratio, risk ratio, confidence interval and p-value [16] .
The variability between participants, interventions and outcomes results in clinical heterogeneity, or clinical diversity. The combination of the clinical heterogeneity, variability in study design and risk of bias gives rise to the statistical heterogeneity, as seen between the retrieved studies [16] , which may cause inconsistencies and inaccuracies in the overall data. There are several factors which may contribute towards statistical heterogeneity of data collected between the studies. These include:
• The varying quality of the studies, caused by discrepancies in the detailing of each of the studies. In particular, the abstract of a paper by Fielding et al., (2013) [22] had a low NewcastleOttawa Quality Assessment score and QUADAS-II score, as it contained little information about the study, where as the paper by Phylipsen et al., (2012) [21] had very high quality scores, as it reported a more detailed description of the study;
•
The study sizes, ranging from 2 to 52 participants in the study. The paper by Cheung et al., (1996) [20] only has two test subjects, therefore, despite 100% accuracy rating this may be a less accurate or reliable result when included in a pooled average of results;
• The paper by Cheung et al., [20] was published in 1996, therefore, may use obsolete or aged methods for cffDNA extraction and analysis;
• The differing methods of isolating foetal DNA from maternal blood and the following techniques for DNA analysis;
• The differing genetic backgrounds of the participants and, therefore, the different genetic variation of SCD, which would consequently have different SNPs, thereby requiring different identification markers [21] ;
• The experiments were performed by separate research groups, which would result in different sets of random and systematic errors, and would subsequently alter the accuracy of the data collected.
Implications for Clinical Practice
These results, therefore, indicate that with further research, the use of cffDNA for NIPD of SCD has the potential to be an accurate technique for clinical testing, replacing the current invasive methods of testing, such as amniocentesis and chorionic villus sampling. This would diminish the potential harm caused to the mother and foetus during genetic testing.
Additionally, the cost for NIPD in general is very expensive. It has been reported that NIPD in China may cost between $487 and $587, whereas amniocentesis costs approximately $326, and in Brazil, NIPD may cost $1,492, whereas amniocentesis costs $426, on average [25] . Therefore, unlike in countries with subsidised health care, such as the United Kingdom, it is personally very expensive for the parents to undergo a non-invasive procedure in order to test for genetic abnormalities and, therefore, this may impact the acceptance of this procedure to be used in the clinic and may deter patients from undergoing this procedure [25] . Furthermore, when compared to the cost of post-natal testing, of which reports state some techniques can cost as little as $0.50 per test [28] , it is obvious that further research needs to be performed in order to increase efficiency of NIPD testing at a minimal cost, so that it may be best applied to the global population.
CONCLUSION
CffDNA for non-invasive prenatal SCD diagnosis appears to have the potential to be an accurate technique for the testing of this genetic disease, despite not currently indicating a proportion of correct diagnosis results, which would encourage the technique for clinical implementation. Whilst there are currently very limited data on the use of this technique for the specific testing of SCD, there is great opportunity for further research into the standardisation and clinical application of this procedure. Therefore, it is imperative that a reliable, sensitive and specific method for prenatal testing of an unborn foetus for this disease is developed, so the parents of the foetus can be prepared to deal with this lifelong disease. Furthermore, low cost but high quality testing without risking the health of the mother and unborn foetus in the process is absolutely necessary. The use of cffDNA for NIPD of SCD has the potential to be an optimal alternative to amniocentesis, chorionic villus sampling or cordocentesis with regards to accuracy, as well as maternal and foetal safety of these procedures, however, more research needs to be performed in order to fully determine the sensitivity and specificity of this test, before it can become the preferred method of prenatal diagnosis for SCD.
